Kenneth Bloom
Head of Pathology Nucleai
Seminars
Tuesday 4th November 2025
Discussing a Novel AI Spatial Platform to Inform Your ADC Biomarker Strategy
2:30 pm
- Understanding the complexity of ADC therapies, including their intricate MoA, the challenges posed by tumor heterogeneity, the role of the tumor microenvironment, and bystander effect impact
- Demonstrating how computational pathology can better stratify patients most likely to benefit from ADCs
- Seeing how an AI-enhanced pipeline can help better identify targets for ADC and emerging multi-specific therapies
